Puma Biotechnology (PBYI) Invested Capital (2017 - 2025)
Puma Biotechnology (PBYI) has disclosed Invested Capital for 9 consecutive years, with $152.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Invested Capital rose 11.21% year-over-year to $152.9 million, compared with a TTM value of $152.9 million through Dec 2025, up 11.21%, and an annual FY2025 reading of $152.9 million, up 11.21% over the prior year.
- Invested Capital was $152.9 million for Q4 2025 at Puma Biotechnology, up from $149.0 million in the prior quarter.
- Across five years, Invested Capital topped out at $152.9 million in Q4 2025 and bottomed at -$10.9 million in Q3 2021.
- Average Invested Capital over 5 years is $70.0 million, with a median of $61.2 million recorded in 2021.
- The sharpest move saw Invested Capital plummeted 307.6% in 2021, then surged 983.4% in 2022.
- Year by year, Invested Capital stood at -$2.4 million in 2021, then soared by 983.4% to $21.6 million in 2022, then surged by 304.66% to $87.4 million in 2023, then surged by 57.2% to $137.5 million in 2024, then rose by 11.21% to $152.9 million in 2025.
- Business Quant data shows Invested Capital for PBYI at $152.9 million in Q4 2025, $149.0 million in Q3 2025, and $138.7 million in Q2 2025.